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Engineering of stealth (maghemite/PLGA)/chitosan
(core/shell)/shell nanocomposites with potential
applications for combined MRI and hyperthermia
against cancer
Fátima Fernández-Álvarez, a Carlos Caro, b Gracia Garcı́a-Garcı́a, ac
Marı́a Luisa Garcı́a-Martı́n bd and José L. Arias *aef
(Maghemite/poly(D,L-lactide-co-glycolide))/chitosan (core/shell)/shell nanoparticles have been prepared
reproducibly by nanoprecipitation solvent evaporation plus coacervation (production performance E 45%,
average size E 325 nm). Transmission electron microscopy, energy dispersive X-ray spectroscopy,
electrophoretic determinations, and X-ray diffraction patterns demonstrated the satisfactory embedment
of iron oxide nanocores within the solid polymer matrix and the formation of an external shell of
chitosan in the nanostructure. The adequate magnetic responsiveness of the nanocomposites was
characterized in vitro by hysteresis cycle determinations and by visualization of the nanosystem under
the influence of a 0.4 T permanent magnet. Safety and biocompatibility of the (core/shell)/shell particles
were based on in vitro haemocompatibility studies and cytotoxicity tests against HFF-1 human foreskin
fibroblasts and on ex vivo toxicity assessments on tissue samples from Balb/c mice. Transversal
relaxivities, determined in vitro at a low magnetic field of 1.44 T, demonstrated their capability as T2
contrast agents for magnetic resonance imaging, being comparable to that of some iron oxide-based
contrast agents. Heating properties were evaluated in a high frequency alternating electromagnetic
gradient: a constant maximum temperature of E46 1C was generated within E50 min, while
antitumour hyperthermia tests on T-84 colonic adenocarcinoma cells proved the relevant decrease in
cell viability (to E 39%) when treated with the nanosystem under the influence of that electromagnetic
field. Finally, in vivo magnetic resonance imaging studies and ex vivo histology determinations of
iron deposits postulated the efficacy of chitosan to provide long-circulating capabilities to the
nanocomposites, retarding nanoparticle recognition by the mononuclear phagocyte system. To our
knowledge, this is the first study describing such a type of biocompatible and long-circulating
nanoplatform with promising theranostic applications (biomedical imaging and hyperthermia) against
cancer.
Introduction
The introduction of Nanotechnology in the cancer arena is actively
revolutionizing the management of this worrying and severe
disease.1–4 Talking about chemotherapy, antitumour drugs and/
or genes have generated significant therapeutic outcomes (when
given alone or in combination regimens), and the formulation of
biodegradable and biocompatible nanoparticles (NPs) has facili-
tated the controlled and site-specific delivery of these agents.5,6
This important input has contributed to overcome the typical
problems of cancer chemotherapy (responsible for the use of the
high doses inducing acute toxicity):7,8 (i) unfavourable physical
chemistry (e.g. hydrophobic character) and pharmacokinetics
(rapid metabolism and short plasma half-life) of the active agent;
(ii) widespread biodistribution and extravasation in non-targeted
areas; (iii) low selectivity toward malignant cells; and (iv) suscepti-
bility to induce chemoresistance in cancer cells.
These barriers have also been described for signal emitters
or contrast agents, such as radionuclides, luminophores, or
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magnetic resonance imaging (MRI) contrast agents, therefore
defining the little sensitivity and limited efficacy of current
imaging techniques in the (early) diagnosis and follow-up of
cancer. Nanoparticulate systems have been engineered satis-
factorily to beat these challenges.9,10 They even have generated
promising results when expanded to alternative treatment
options against cancer, i.e. hyperthermia,11,12 photodynamic
therapy,13,14 and photothermal therapy.15,16
Introducing passive and active targeting concepts in the
engineering of all these nanosystems has been described to
optimize their in vivo fate (and efficacy).17,18 Passive targeting
strategies, taking advantage of the enhanced permeability and
retention (EPR) effect, are based on the formulation of long-
circulating or stealth NPs.19 They are typically prepared by
coating the particle surface with a hydrophilic polymer, typi-
cally poly(ethylene glycol) (PEG), to protect the NP from opso-
nization by repelling plasma proteins.20
With respect to the active targeting strategies, they are
characteristically based on: (i) the surface functionalization of
NPs with molecules that can bind selectively to ligands unique
to cancer cells (ligand- or receptor-mediated targeting),21,22
and/or (ii) the engineering of stimuli-sensitive carriers. The
latter are NPs that can experience alterations in their structure
and physical characteristics under changes in the environment,
resulting in the specific (triggered) release of therapeutics at the
targeted site.23,24
Building nanostructures joining both passive and active
targeting functionalities has further resulted in better results
in the diagnosis25 and therapy26,27 of cancer. Superpara-
magnetic iron oxides, e.g. magnetite (Fe3O4) and maghemite
(g-Fe2O3), can contribute notably to the formulation of these
advanced nanoplatforms, owing to their magnetic targeting
capacity,28–30 in combination with their versatility as agents
in both magnetic antitumour hyperthermia31,32 and MRI.33,34
As a consequence, they are considered of interest when engi-
neering theranostic NPs against cancer,29,35,36 in which they
can assure MRI contrast, antitumour magnetic hyperthermia,
and magnetic targeting and magnetic-based cargo delivery
functionalities. The structure of these advanced nanoplatforms
based on iron oxides frequently involves a core/shell construc-
tion in which the magnetic colloids are embedded in a
polymer37,38 or lipid39,40 matrix, for the enrichment of their
properties, such as colloidal stability, biocompatibility, safety,
bioavailability, targeting and controlled release. In this context,
poly(D,L-lactide-co-glycolide) (PLGA), a Food and Drug Admin-
istration (FDA)-approved polymer, demonstrated outstanding
applications due to its biocompatibility, biodegradability, and
drug vehiculization capabilities (adequate drug loading values
along with biphasic controlled drug release properties).41–43
Remarkably, the latter characteristic includes a pH-triggered
drug delivery to the cancer site, given the accelerated degradation
of the polymer at the acidic intratumoural pH.44,45 Furthermore,
PLGA has been also proposed to formulate thermoresponsive
delivery systems facilitating a heat-triggered drug release at the
targeted site.46–48 All these are the main reasons that could
justify the inclusion of the polymer as the inner shell of a
(core/shell)/shell nanostructure. As a result, the PLGA shell
would provide pH- and heat (hyperthermia)-responsive function-
alities to this composite nanoplatform for the selective delivery
of therapeutic molecules (drugs and/or genes) to malignant cells.
Chitosan (CS) has also been used to prepare biocompatible,
biodegradable, and nontoxic magnetic NPs,37,49–51 providing
controlled release of many active agents. This water-soluble,
low molecular weight (MW), biodegradable and biocompatible
polymer has recently been proposed as an interesting alternative
to PEG chains when engineering stealth NPs. It can provide a
hydrophilic stealth coating on NPs to camouflage them from the
mononuclear phagocyte system (MPS), thus preventing prema-
ture clearance from systemic circulation.52–54 The positive
surface electric charge provided by CS to the NP surface could
also contribute to the lack of binding with opsonins, thereby
contributing to evading phagocytosis and prolonging blood
circulation.55
Surface modification of PLGA NPs with a CS shell is possible
owing to attractive electrostatic interactions between the
negatively charged PLGA particles and the positively charged
CS.56,57 Additional benefits of CS functionalization are the
optimization of the sustained drug release capabilities58–60
and the enhancement of the uptake by targeted cells.61–64
Therefore, CS surface coating onto these drug- and gene-
loaded PLGA nanosystems may help in improving their bio-
distribution and therapeutic effects.65,66 This conceptualization
has been recently applied to the formulation of magnetopoly-
mer particles, in which a (Fe3O4/PLGA)/CS (core/shell)/shell
structure was described.67–69
In this contribution, we develop a reproducible procedure to
formulate (g-Fe2O3/PLGA)/CS NPs. Generation of this (core/
shell)/shell nanostructure was evaluated by transmission elec-
tron microscopy and elemental analysis, and by comparing the
electrical surface properties of the nanocomposite to those of
g-Fe2O3/PLGA and CS particles. Mineralogical crystallinity of
the g-Fe2O3 nuclei embedded in the polymer matrix was inves-
tigated by X-ray diffractometry. Short-term colloidal stability in
water was evaluated at 4.0 1C, while magnetic evaluations
helped in analysing the magnetic responsiveness. Toxicity
assessment was focused on blood compatibility studies, cyto-
toxicity tests on HFF-1 human foreskin fibroblasts, and hae-
matoxylin and eosin (H&E) staining of tissue samples from
Balb/c mice. A preliminary analysis of the potential use of the
nanocomposites as MRI contrast agents was accomplished
in vitro, while their antitumour hyperthermia capabilities were
analysed under the influence of a high frequency alternating
electromagnetic field in T-84 cells. Finally, in vivo distribution of
the particles was determined by dynamic MRI and by Prussian
blue (PB) visualization of iron deposits in tissue samples.
Materials and methods
Materials
All chemicals were of analytical quality and were used as received
without further purification. Fe(NO3)39H2O (MW: 404 g mol1),
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FeCl24H2O (MW: 198.81 g mol1), KNO3, HClO4 (70%, American
Chemical Society, ACS specification), HCl (37%, ACS specifica-
tion), EtOH 961, and CH3COOH (Z98%, ACS specification)
from VWR International, LLC (Spain). Low MW CS (E50 000 to
190 000 Da, determined by viscosity measurement; polydisper-
sity not determined by the laboratory; 75–85% deacetylated;
99% purity level), Resomers RG 502 H [PLGA, 50 : 50 poly(D,L-
lactide) : poly(glycolide), MW E 7000 to 17 000 Da, inherent
viscosity E 0.16 to 0.24 dL g1], ethylenediaminetetraacetic acid
(EDTA), NaH2(C3H5O (COO)3), 40,6-diamidino-2-phenylindole
(DAPI) dihydrochloride, phosphate buffered saline (PBS),
3-(4,5-dimethylthiazol-2-yl)-3,5-diphenyl tetrazolium bromide
(MTT) solution, xylene, CH2O, K4[Fe(CN)6], and ethanol 991 from
Merck KGaA (Germany). Kolliphors P-188 from BASF (Germany).
Cl3FeH12O6 (MW: 270.32 g mol
1), polyvinyl alcohol (PVA, MW:
72 000 g mol1), HPLC-grade acetone, and NH3 (30%, ACS
specification) from Panreac (Spain). Na2SO4 and oleic acid
(Z99%, ACS specification) from Guinama S. L. (Spain). TO-
PROs-3 iodide and dimethyl sulfoxide (DMSO) from ACROS
Organicst (Belgium). Dulbecco’s modified Eagle’s medium
(DMEM), fetal bovine serum (FBS), 2 mM L-glutamine, Gibcot
penicillin–streptomycin solution (100 IU mL1), and Tritons
X-100 from ThermoFisher Scientific Inc. (USA). Deionized
and filtered water was used in all the experiments (Milli-Q
Academics, Millipore, France).
Formulation of (c-Fe2O3/PLGA)/CS (core/shell)/shell
nanocomposites
Fe3O4 NPs were obtained by chemical co-precipitation.
70 The
reaction started with the simultaneous and slow addition of
40 mL of 1 M FeCl3 solution and 10 mL of 2 M FeCl2 solution
(in 2 M HCl) to 0.5 L of 0.7 M NH3 solution, at room
temperature and under mechanical stirring (700 rpm; IKAs
Eurostar 60 Digital Constant-Speed Mixer, Germany). Stirring
was continued for 30 min. Long-term stabilization of the Fe3O4
particles was then achieved by magnetic isolation (permanent
magnet of 0.4 T) from the NH3 media and re-dispersion in
0.25 L of 2 M HClO4 solution. After 12 h of contact, the NPs
were isolated using a magnet (0.4 T), and their oxidation into
g-Fe2O3 was accomplished with Fe(NO3)3 (0.6 L, 0.34 M) at 90 1C
during 30 min.71 Finally, cleaning of the g-Fe2O3 NPs was done
by repeated cycles of centrifugation (30 min at 8500 rpm,
Centrifuge 5804; Eppendorf Ibérica S. L. U., Spain) until the
conductivity of the supernatant was r10 mS cm1 (Crison
Microcm 2202 conductivity meter, Hach Lange Spain S. L. U.,
Spain).
Incorporation of oleic acid onto the surface of iron oxide
NPs has been described to result in a change in the surface
characteristics from hydrophilic to hydrophobic.72,73 This
surface transformation in the g-Fe2O3 particles may favour
their incorporation into the PLGA matrix when preparing the
g-Fe2O3/PLGA (core/shell) particles. To that aim, 3.5 mL of an
ethanolic solution of oleic acid (1%, v/v) was added under
sonication (42 kHz sonication frequency, 100 W output power;
Bransonics ultrasonic bath, Branson Ultrasonics Corporation,
USA) to 14.25 mg of iron oxide nuclei (1 : 1.25 iron : oleic molar
ratio).74 Sonication was continued for 60 min. The oleic acid-
treated g-Fe2O3 nanocores were isolated from the EtOH
solution using a permanent magnet of 0.4 T and washed twice
with 1 mL of acetone.
The formulation of the g-Fe2O3/PLGA (core/shell) particles
(of 3 : 4 g-Fe2O3 : PLGA weight ratio) was based on the nano-
precipitation solvent evaporation technique, which has been
previously used to prepare pure PLGA NPs.21,75,76 The proce-
dure started with the addition of an organic phase containing
PLGA and the oleic acid-modified iron oxide nuclei (19 mg
and 14.25 mg in 5 mL of acetone, respectively) to 10 mL of
an aqueous solution of PVA (1%, w/v), under sonication
(Branson Sonifier 450, Emerson Electric Co., USA). The micro-
tip of the ultrasonic homogenizer was placed in the aqueous
phase, leaving 1 cm distance from the bottom of the vial.
To minimize the evaporation of the liquid, an aluminium
foil was placed over the opening of the vial. Pulsed mode, with
a cycle of 40%, sonication output of 20%, and sonication
time of 1 min, avoided foaming and enabled adequate tem-
perature control. The sample vial was surrounded with ice
during the sonication process. Acetone was evaporated to
obtain an aqueous dispersion of g-Fe2O3/PLGA NPs (Büchi
Rotavapors rotary evaporator, Büchi, Switzerland), and the
NPs were then cleaned by repeated magnetic separation from
the aqueous medium (0.4 T permanent magnet) and redisper-
sion in water, until the conductivity of the supernatant was
r10 mS cm1.
Finally, (g-Fe2O3/PLGA)/CS (core/shell)/shell particles (of 4 : 3
g-Fe2O3/PLGA : CS weight ratio) were obtained by a coacervation
method, which was also used to obtain pure CS NPs.77–79
Initially, 10.5 mg of CS was progressively dissolved in 25 mL
of an aqueous solution of acetic acid (2%, v/v) containing
1% (w/v) Kolliphors P-188, under mechanical stirring
(1000 rpm), and 14 mg of g-Fe2O3/PLGA NPs was then homo-
geneously dispersed in this aqueous phase under mechanical
stirring (700 rpm). At that moment, 6.25 mL of 20% (w/v)
solution of Na2SO4 was added drop-wise (1.25 mL min
1) under
sonication (cycle of 50%, sonication output of 20%, and sonication
time of 15 min) to obtain the aqueous dispersion of (core/shell)/
shell particles. The (g-Fe2O3/PLGA)/CS NPs were cleaned
repeatedly by magnetic separation and redispersion in water
until the conductivity of the supernatant was r10 mS cm1.
In contrast, cleaning of the pure CS particles was achieved
by repeated cycles of centrifugation (30 min at 9500 rpm,
Centrikon T-124 high speed centrifuge, Kontron, France) and
redispersion in water, until the conductivity of the supernatant
was r10 mS cm1.
All experiments were carried out in triplicate (n = 3), and the
particle production performance (yield, %) was determined by
using eqn (1):
Yield ð%Þ ¼ amount of NPs obtained ðmgÞ
summation of materials used in the preparation of these NPs ðmgÞ  100 (1)
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Characterization
Particle size, size distribution (polydispersity index, PdI), and
zeta potential (z) were determined after dilution of the colloids
in water (E0.1%, w/v) (n = 3) (Zetasizer Nano-ZS, Malvern
Instruments Ltd., UK). The cell temperature was 25.0  0.5 1C,
and the detection angle was 601.
High resolution transmission electron microscopy (HRTEM),
high-angle annular dark field scanning transmission electron
microscopy (HAADF-STEM), and annular bright field scanning
transmission electron microscopy (ABF-STEM) (Titan G2 60-300
FEI microscope, Thermofisher Scientific Inc., USA; operating at
an accelerating voltage of 300 kV) helped in visualizing the
nanostructures and in evaluating the complete coating of the
cores by the polymeric matrices. Drops of the dilute aqueous NP
dispersions (E0.1%, w/v) were poured on formvar/carbon-coated
copper microgrids and dried in a convection oven (25.0  0.5 1C,
24 h) (J. P. Selecta, S. A., Spain). Elemental analysis was
performed during the TEM measurements by using an energy
dispersive X-ray (EDX) spectrometer (Bruker Nano GmbH,
Germany).
Short-term colloidal stability at 4.0  0.5 1C was tested in
water (n = 3). The aqueous dispersion of (core/shell)/shell NPs
(1 mg mL1, pH E 6) was stored at this temperature, and the
evolution of size, PdI and z values of the particles was measured
as a function of time following storage. These are parameters
that are considered as benchmarks for characterizing the
stability of colloidal systems.29 At each sampling time a for-
mulation was tested and not returned to the storage conditions.
CS coating onto the (g-Fe2O3/PLGA) particles was qualita-
tively evaluated by determining the influence of pH (pH values
from 3 to 9, in the presence of 103 M KNO3) on the z values
of these NPs. Determinations were done at room temperature
(n = 12), after 24 h of contact under mechanical stirring
(200 rpm, Boeco universal orbital shaker OS-10, Boeco, Germany).
Mineralogical purity and crystallinity of iron oxide-based
NPs are important factors that contribute to their magnetic
responsiveness.29,80,81 In view of this, characterization of the
internal structure of the g-Fe2O3 nuclei and the (g-Fe2O3/PLGA)
and (g-Fe2O3/PLGA)/CS particles was done by X-ray diffracto-
metry (Philips PW1710 diffractometer, The Netherlands), using
the Debye–Scherrer method with Cu-Ka radiation of l = 1.5405 Å.
The magnetic characteristics of the (core/shell) and (core/
shell)/shell NPs were determined at 25.0  0.5 1C, under the
influence of a magnetic field ranging from 4000 to 4000 kA m1
(Manics DSM-8 vibrating magnetometer, France). Additionally,
the magnetic field responsive behaviour of a 0.1% (w/v) aqueous
NP dispersion was qualitatively analysed by optical microscope
visualization of the colloid under exposure to a 0.4 T permanent
magnet (Olympus BX40F4 microscope, Olympus Optical Co. Ltd,
Japan). A Gilmont (USA) micrometer syringe was used to deposit
gently one droplet (E10 mL) of the colloid on a dry and clean
microscope glass slide. The magnet was situated at a distance of
3 cm from the centre of the droplet, and images were then
captured with a video camera at t = 5 s.
Iron concentration was determined by inductively coupled
plasma-high resolution mass spectrometry (ICP-HRMS, Element
XR High Resolution ICP-MS system, ThermoFisher Scientific
Inc., USA).82 Prior to analysis, the (g-Fe2O3/PLGA) particles and
(g-Fe2O3/PLGA)/CS particles were disintegrated by adding 2.5 mL
of aqua regia (3 : 1 HNO3 : HCl molar ratio) to 25 mL of 0.1% (w/v)
aqueous NP dispersion. After 12 h of contact, water was added to
the volumetric flask (final volume: 25 mL) and the sample was
analysed.
Longitudinal (r1) and transversal (r2) relaxivities of (core/
shell) NPs and (core/shell)/shell NPs were determined in vitro at
a low magnetic field (1.44 T) and 37.0 0.5 1C (Bruker Minispec
MQ-60 spectrometer, Bruker BioSpin, Germany),83 using iron
concentrations ranging from 0.25 to 2.00 mM. Transverse
(or spin–spin) relaxation time (T2) values were measured by
using the standard Carr–Purcell–Meiboom–Gill (CPMG) pulse
sequence, while the longitudinal (or spin–lattice) relaxation
time (T1) was measured using the standard inversion-recovery
pulse sequence.
Haemocompatibility
Interaction of (g-Fe2O3/PLGA) NPs and (g-Fe2O3/PLGA)/CS NPs
with blood components was evaluated to postulate their possi-
bilities for clinical applications, i.e. magnet-guided chemother-
apy plus hyperthermia. The methodology has been detailed
previously,21,39,84,85 being appropriate in the evaluation of
nanoformulations. In brief, blood samples were obtained from
two healthy female adults (24 and 45 year old), and poured into
flasks containing EDTA (prior to haemolysis, and platelet
activation assays) or NaH2(C3H5O (COO)3) (prior to comple-
ment system activation, and plasma clotting time experiments).
The colloids were kept in contact with blood aliquots to
evaluate their impact on erythrocytes, coagulation, and the
complement system (n = 3). PBS was used as a negative control.
A validated ultraviolet-visible (UV-Vis) spectrophotometric
method was used in the study.
In vitro proliferation studies
HFF-1 human foreskin fibroblasts were cultured in DMEM
supplemented with 2 mM L-glutamine, 10% FBS and 1%
penicillin–streptomycin, at 37.0  0.5 1C in a humidified
atmosphere of 5% CO2 [MCO-19AIC(UV) CO2 incubator, Sanyo,
Japan]. Then, the cells in the exponential growth phase were
seeded into 96-well plates (104 cells per well) and were pre-
incubated for 24 h (37.0  0.5 1C, 5% CO2), and the medium in
the wells was replaced with fresh medium containing g-Fe2O3/
PLGA or (g-Fe2O3/PLGA)/CS particles (0.1 to 100 mg mL
1 of iron
concentration).
Following the ISO-10993-5 standard,86 cell viability was
tested (in quadruplicate) by the MTT proliferation assay, by
determining mitochondrial dehydrogenase activity. After 24 h
of contact, 200 mL of MTT solution in cell culture medium
(0.5 mg mL1) was added to each well. After incubation for 2 h
at 37.0  0.5 1C and 5% CO2, the culture medium was removed
and the resultant formazan crystals were solubilized with
200 mL of DMSO. The absorbance of converted dye, which is
proportional to the number of viable cells (metabolically active
cells), was measured at 550 nm using a Dynatech MR7000
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microplate reader (Dynatech Laboratories, Inc., USA). Tritons
X-100 (1%, v/v) was added to the positive control wells. Relative
cell viability (RCV, %) and the error related to control wells
containing cell culture medium without NPs were calculated by
eqn (2) and (3), respectively:
RCV ð%Þ ¼ Atest  Apositive controls for theNPs
Anegative controls for theNPs  Apositive controls for theNPs
 100
(2)









where A is the absorbance and s is the standard deviation (SD).
HFF-1 cells were also cultured, similarly as described above,
for the cell morphology studies, in quintuplicate. After 24 h of
contact with the g-Fe2O3/PLGA or (g-Fe2O3/PLGA)/CS particles
(0.1 to 100 mg mL1 of iron concentration), Tritons X-100
(1%, v/v) was added to the positive control wells. After 15 min, all
the wells were stained with DAPI (dilution 1 : 3000) to label the
cell nucleus and with TO-PROs-3 iodide (dilution 1 : 1000) to
label only dead cells. 10 random image fields captured per well
were analysed (20 long working distance, numerical aperture
0.45, air objective lens; Operettas High Content Imaging System,
PerkinElmer, Inc., USA) being taken for each field fluorescence
image for DAPI and TO-PROs-3 iodide, plus a bright field image.
Cell mortality (%) was calculated automatically by Operettas
Harmony software (PerkinElmer, Inc., USA), whereby live or
dead nuclei were identified from the DAPI staining. Dead cells
(%) were then determined by the number of nuclei presenting
also high levels of TO-PROs-3 iodide staining.
Magnetic fluid hyperthermia experiments
The in vitro heating behaviour of an aqueous dispersion of
(g-Fe2O3/PLGA)/CS NPs (10 mg mL
1, 5 mL) compared to a
control formulation (i.e. aqueous medium without particles)
was investigated at 25.0  0.5 1C (n = 3). To that aim, a high
frequency alternating electromagnetic field induced by a power
supply equipped with a solenoid was used (diameter: 20 mm;
length: 100 mm; number of spirals: 70). Magnetic field fre-
quency and intensity values were 250 kHz and 4 kA m1,
respectively, which were within the average commonly fixed
to do such characterization37,39,49,87 and below the human
tolerance threshold.88 Temperature data were continuously
logged using a fiber optic thermometry unit connected to a
laptop computer.
The antitumour magnetic hyperthermia activity of the
(g-Fe2O3/PLGA)/CS NPs was evaluated on the T-84 colonic
adenocarcinoma cell line (American Type Culture Collection,
USA). Detailed description of the procedure can be found in the
literature.39,89,90 Briefly, cells were seeded into 24-well plates
(104 cells per well) and incubated for 2 h in the presence
(or absence) of the NPs (0.4%, w/w) (37.0  0.5 1C, 5% CO2).
Then, cell suspensions were centrifuged (10 min at 4000 rpm)
to separate the cells from the unbound or weakly bound magnetic
nanocomposites, and the cell pellets were re-suspended in 200 mL
of culture medium. The oscillating electromagnetic gradient was
then applied (or not) to the cell suspensions for 1 h, and the cells
were incubated at room temperature for 30 min and then washed
twice in PBS and suspended in the culture medium. Finally, the
cells were seeded into 24-well plates (104 cells per well) and kept
under culture conditions for 48 h (37.0  0.5 1C, 5% CO2). Finally,
cell viability was evaluated by the MTT-based colorimetric assay.
In vivo MRI studies
All the in vivo experiments were done in the BIONAND Animal
Experimentation Service. They were approved by the local
Animal Care Committee and performed in compliance with
the EU Directive 2010/63/EU (2010) and the Spanish legislation
for the care and use of laboratory animals (R.D. 53/2013).
Male Balb/c mice, 22 g in weight (Janvier Labs, France), were
anesthetized with 1% isoflurane, and their tail veins were
cannulated. Then, the mice were introduced in the MRI system.
Respiratory signals and body temperature were monitored
throughout the MRI experiment. The (g-Fe2O3/PLGA) or
(g-Fe2O3/PLGA)/CS NPs were intravenously injected at an iron
concentration of 5 mg kg1. The study was performed in
triplicate on a Bruker BioSpecs 9.4 T animal MRI system
(BioSpec 94/20 USR superconducting magnet system, Bruker
BioSpin, Germany) equipped with a 400 mT m1 gradient and a
40 mm quadrature bird-cage resonator.
High resolution T2-weighted images were acquired using a
turbo-RARE sequence with respiratory gating (echo time, TE:
16 ms; repetition time, TR: 1000 ms; averages: 4; in-plane
resolution: 156 mm; and slice thickness: 1 mm). Quantitative
T2 measurements were performed using a multi-echo spin echo
sequence (TE ranging from 7 to 448 ms, TR: 3500 ms, field of
view: 4 cm, matrix size: 128  128, and slice thickness: 1 mm).
Time-courses were followed by using a turbo-RARE sequence
with the parameters indicated above, except for only one
average to improve temporal resolution (one image every 30 s).
The acquisition scheme was as follows: T2-weighted, quantitative
T2 map, intravenous injection of the NPs, time-course for 35 min,
T2-weighted, and quantitative T2 map. The first 35 min time-
courses were analysed semi-quantitatively using eqn (4):
RE ð%Þ ¼ It  Io
Io
 100 (4)
where RE is the modulus of relative signal enhancement, It is the
signal intensity at any given time after injection of NPs, and I0 is the
signal intensity before injection.
Biodistribution was characterized by quantitative T2 map-
ping at 0, 1, and 24 h. Average T2 values were calculated within
different regions of interest placed on the liver, spleen, kidneys,
and muscle, as previously described.91,92
Ex vivo histology evaluation of iron deposits and toxicity
assessment
Histology was determined by conventional optical microscopy
visualization of tissue samples, at 24 h post-intravenous injec-
tion of (g-Fe2O3/PLGA) and (g-Fe2O3/PLGA)/CS NPs. Mice were
sacrificed and the liver, kidney, spleen, lung and heart were
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extracted. Tissues were fixed in 4% (w/v) aqueous CH2O
solution (buffered to pH 7.0  0.5) for 48 h, changing this
liquid medium after 24 h. Then, the tissue samples were
dehydrated with EtOH and soaked in paraffin (at 56.0 
0.5 1C for 2 h, under mechanical stirring) (LEICA TP 1020
Semi-enclosed Benchtop Tissue Processor, Leica Biosystems
Nussloch GmbH, Germany). Finally, the samples were
embedded in paraffin (Leica EG1150 Modular Tissue Embed-
ding Center, Leica Biosystems Nussloch GmbH, Germany), and
then cut into 7 mm-sized sections using a microtome blade
(Thermo Scientifict HM 360 microtome, ThermoFisher Scien-
tific Inc., USA).
Tissue samples were stained with Prussian blue (PB) to
visualize iron deposits. To that aim, the tissue slides were
deparaffinized, rehydrated, and immersed for 30 min in a
freshly prepared mixture of equal parts of 20% (v/v) HCl and
10% (w/v) K4[Fe(CN)6] solution. The tissue sections were then
washed thrice in water and counter stained with nuclear fast red for
5 min. Finally, the sections were rinsed twice with distilled water,
EtOH 100%, followed by 100% xylene, and mounted with coverslips
for observation under an optical microscope.
Tissue samples were also stained with haematoxylin and
eosin (H&E) to assess tissue architecture. Deparaffinization and
rehydration of the tissue slides were done before staining with
H&E. Staining was possible by immersion of the samples for
5 min in H, washing twice in water, and immersion of the tissue
samples in E for 2 min. The slides were then dehydrated
in ascending grades of EtOH (from 70 to 100%), cleared in
100% xylene, and mounted using glass coverslips for observa-
tion under a microscope.
Statistical analysis
Statistical analyses were done using the IBM SPSS Statistics
software package (version 26.0; IBM Corporation, USA). Experi-
mental data were expressed as mean value  SD. Student’s
t-test or two-way analysis of variance helped to compare results
considering 95% confidence interval. Differences were consi-
dered statistically significant at p o 0.05.
Results and discussion
Characterization
The in vivo fate and use of magnetic colloids in biomedicine is
considerably defined by their size and surface electric charge,
among other relevant characteristics. Such properties can be
tailored when engineering the iron oxide-based particles to
prevent capture by the MPS.7,29 This may further facilitate
reaching the malignant tissue by passing through the gap
junction between endothelial cells of the leaky tumour vascu-
lature (up to E600 nm).93,94
The mean size (and PdI) of g-Fe2O3 nuclei, pure CS particles,
and (g-Fe2O3/PLGA) NPs was determined by photon correlation
spectroscopy (PCS), and was found to be 9.1 3.2, 353.4 20.6,
and 285.3  4.2 nm, respectively. The formulation of (g-Fe2O3/
PLGA)/CS (core/shell)/shell NPs (of 4 : 3 g-Fe2O3/PLGA : CS
weight ratio) by coacervation reported adequate particle pro-
duction performances (E45%), and appropriate size (325.8 
8.5 nm, compatible with parenteral administration) and z
values (23.3  0.4 mV). The stealth coating and positive surface
electric charge provided by CS to the g-Fe2O3/PLGA nanostruc-
ture are expected to prevent the premature clearance of the
(core/shell)/shell NPs from the systemic circulation,52–55 thus
favouring appropriate plasma half-lives to reach the tumour
site and provide clinically relevant concentrations of any given
therapeutic agent. Furthermore, these positive z values may
facilitate NP internalization by negatively charged cancer cells,
thus possibly assuring the deep contact of the therapeutic
molecule with intracellular targets.55,61–64,95,96
The results from short-term stability studies are compiled in
Table 1. From the results, it could be hypothesized that the
preparation technique may be used in the formulation of
appropriately stabilized (core/shell)/shell NPs. In fact, no NP aggre-
gation was observed, and no appreciable change in the size and
surface electric charge of the nanocomposites was detected by PCS
after 1 month of storage at 4.0  0.5 1C in water (Table 1).
HRTEM, HAADF-STEM, and ABF-STEM photographs ratified
that the iron oxide nuclei were embedded in the polymeric
matrices (Fig. 1a–d), while the EDX Fe and N element mappings
of these (core/shell)/shell particles demonstrated the homoge-
neous distribution of g-Fe2O3 nuclei within the NP matrix
(Fig. 1e) and the coating of CS onto the g-Fe2O3/PLGA nano-
structure (Fig. 1f). Aggregation of NPs observed in the figure
was associated with the method of sample preparation (drying)
for electron microscopy observations.38,49,97,98
EDX analyses also revealed the existence of the elements Fe,
C, N, and O for the NPs (Fig. 1g). The Fe and N elements arise
from the g-Fe2O3 cores and CS shell, respectively. These obser-
vations, combined with data from the electrokinetic character-
ization of the particles (see Fig. 2a), qualitatively confirmed the
formation of the (g-Fe2O3/PLGA)/CS (core/shell)/shell nanos-
tructure. Finally, the use of copper-based grids for EM char-
acterization contributed to the appearance of the Cu element in
this analysis,38 while the presence of Si in the EDX spectra in
such a dilute NP sample could be due to the generation of
secondary fluorescence by the fluorescence detector.99
Table 1 Evolution of size (nm), polydispersity index (PdI) and zeta potential
(z, mV) of (g-Fe2O3/PLGA)/CS particles as a function of time. The aqueous
dispersion of NPs (1 mg mL1, pH E 6) was stored at 4.0 0.5 1C. Experimental
data are expressed as means  SDs of triplicate experiments (n = 3)
Time
(days) Size (nm) PdI z (mV)
0 325.8  8.5 0.367  0.007 23.3  0.4
1 325.8  10.5 0.439  0.070 16.9  0.8
3 332.3  11.3 0.358  0.049 32.8  0.7
5 336.3  2.4 0.335  0.043 20.1  0.4
7 330.2  3.9 0.360  0.047 23.5  0.4
10 333.9  6.4 0.302  0.029 24.0  0.7
14 316.7  13.0 0.291  0.043 12.4  2.6
18 322.6  8.4 0.317  0.006 22.4  0.7
22 337.9  4.2 0.360  0.004 25.9  0.6
30 323.8  30.2 0.377  0.084 25.9  0.6
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Given the different electrokinetic properties of PLGA-based41
and CS-based particles,37 electrophoresis was used to confirm
qualitatively the coating efficiency of CS around the (g-Fe2O3/PLGA)
particles. The study was focused on the effect of pH on the surface
electric charge (z values) of the particles in the presence of 103 M
KNO3 (Fig. 2a). The negative surface charge of these g-Fe2O3/PLGA
particles may come from ionized weak acid groups, probably
carboxylic-end groups.41,100 Under the experimental conditions,
the decrease in absolute z values as pH became more acidic was
associated to the neutralization of the negative regions of the
polymer by adsorption of increasing amounts of H+. On the
opposite, the increasingly negative z values may come from
the increase in OH ions in the dispersion media, which could
tend to favour a gain in H+. In contrast, CS particles were
characterized by positive z values for the whole pH range. The
residual amino groups of CS could be responsible for this
positive electric charge at the polymer–solution interface,37,101
despite the use of SO4
2 as a precipitant and regardless of the
negative groups of the stabilizer Kolliphors P-188 which could
persist on the particle surface even after cleaning. Finally,
Fig. 2a further demonstrates that the z-pH trends of the
(g-Fe2O3/PLGA)/CS NPs were dominated by the CS shell. This
should be the result of the effective CS coating of (g-Fe2O3/
PLGA) particles, leading to a (core/shell)/shell nanostructure
which, from an electrokinetic point of view, is qualitatively
similar to the CS particles.
Taking into account the data from the electrophoretic study,
the mechanism of formation of the (g-Fe2O3/PLGA)/CS (core/
shell)/shell particles could be hypothesized. Attractive electro-
static interactions may take place under the acid condition
characteristics of the aqueous medium where the nanocompo-
sites were formed (pH E 3.3).56,57 These interactions are
expected to occur between the negatively charged g-Fe2O3/PLGA
particles and the positively charged CS matrix at this pH
(see Fig. 2a), favouring the accumulation of CS onto the
g-Fe2O3/PLGA surface, and thus resulting in the formation of
a (g-Fe2O3/PLGA)/CS nanostructure.
Fig. 2b presents the American Society for Testing and
Materials (ASTM) pattern of g-Fe2O3 (ASTM No. 24-81). The
X-ray diffraction patterns of g-Fe2O3 (Fig. 2c), (g-Fe2O3/PLGA)
(Fig. 2d), and (g-Fe2O3/PLGA)/CS (Fig. 2e) particles coincided
well with this pattern. This could be an indication of the
mineralogical purity and high crystalline nature of the synthe-
sized g-Fe2O3 particles (responsible for the superparamagnetic
behaviour and adequate responsiveness to magnetic fields),29
even upon complete coating by both the PLGA and CS matrices.
Fig. 2 (a) Zeta potential (z, mV) of (’) g-Fe2O3/PLGA NPs, (m) CS NPs, and
(&) (g-Fe2O3/PLGA)/CS NPs as a function of pH in the presence of 1 mM
KNO3. Data are presented as mean value  SD (n = 9). Lines are a guide to
the eye and have no other significance. (b) American Society for Testing
and Materials (ASTM) pattern for g-Fe2O3. X-ray diffractograms of (c) g-
Fe2O3, (d) (g-Fe2O3/PLGA), and (e) (g-Fe2O3/PLGA)/CS particles. The
intensity is expressed in arbitrary units (a. u.).
Fig. 1 (a) HRTEM of the (g-Fe2O3/PLGA) (core/shell) particles. (b) HRTEM,
(c) HAADF-STEM, and (d) ABF-STEM images of the (g-Fe2O3/PLGA)/CS
nanocomposites; EDX mapping analysis of the (e) Fe and (f) N elements of
the sample in (c and d); and (g) EDX spectra of the (core/shell)/shell NPs.
Inset: Chemical structures of PLGA and CS. Bar lengths: 300 nm (a) and
100 nm (b, c, d, e, and f).
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2y values of the g-Fe2O3 nuclei embedded in the (core/shell)/
shell NPs were 30.301, 35.641, 43.661, 54.101, 57.361, and 63.041,
and they could be assigned to the (220), (311), (400), (422), (511),
and (440) planes of these iron oxide particles, respectively.102–104
Magnetic responsiveness
The hysteresis cycle of the g-Fe2O3/PLGA and (g-Fe2O3/PLGA)/CS
NPs, plotted in Fig. 3a, characterized their field responsive
behaviour. These particles apparently exhibited a soft
magnetic character, given that the increasing and decreasing
field ramps of the cycle were hardly discernible with the
sensitivity of the instrument used. From the linear portions
(low field) of the curves the initial susceptibility was calculated
to be wi = (0.071 0.009) 103 [and (0.102 0.013) 103] m3 kg1
and the saturation magnetization was 4.98  0.41
(and 7.18  0.59) Am2 kg1 for the (core/shell)/shell (and
core/shell) NPs. The magnetic behaviour of the (g-Fe2O3/PLGA)/CS
particles was quite similar to that of the gFe2O3/PLGA particles,
except that the CS shell reduced slightly the magnetization of the
(core/shell)/shell sample. This could be the consequence, at equal
mass of the sample analysed, of the smaller amount of g-Fe2O3
nanocores contained inside the (g-Fe2O3/PLGA)/CS NPs in compar-
ison to the sample of g-Fe2O3/PLGA particles.
In any case, the appropriate magnetic responsive behaviour
of the (core/shell)/shell NPs was further qualitatively confirmed
by optical microscope visualization of the colloid under
exposure to a permanent magnet (Fig. 3b). The initially homo-
geneous aqueous dispersion of (core/shell)/shell particles chan-
ged markedly, and the formation of chainlike aggregates
parallel to the field lines occurred. This could result from the
notable contribution of the magnetic interaction over the DLVO
colloidal interactions between the NPs (e.g. electrostatic van der
Waals and hydration or acid–base). However, in vivo experi-
ments should be done to clarify if this magnetic responsiveness
could determine the accumulation of the (g-Fe2O3/PLGA)/CS
particles at a targeted site.
Finally, a preliminary study on the potential use of the
nanocomposites as MRI contrast agents was accomplished
in vitro. r1 and r2 values for the g-Fe2O3/PLGA particles were
found to be 0.2 and 48.5 mM1  s1 (Fig. 4a), respectively,
whereas 0.4 and 61.4 mM1  s1 were the r1 and r2 values for
the (g-Fe2O3/PLGA)/CS nanocomposites (Fig. 4b), respectively.
These relaxivities are comparable to those reported previously
for similar iron oxide-based nanostructures77 and iron oxide-
based MRI contrast agents, e.g. Sinerems or Ferumoxytol.105–107
The r2/r1 ratios for g-Fe2O3/PLGA and (g-Fe2O3/PLGA)/CS were
243.5 and 153.5, respectively, suggesting the potential applica-
tion of these NPs as T2 contrast agents.
108,109
In vitro haemocompatibility and cytotoxicity
The contact of nanoparticulate systems with blood components
may lead to adverse effects, e.g., platelet and complement system
Fig. 3 (a) Hysteresis cycles of the g-Fe2O3/PLGA (’) and (g-Fe2O3/
PLGA)/CS (&) particles; and (b) optical microphotographs (magnification
20) of the (core/shell)/shell colloid (0.1%, w/v) under the influence of a
0.4 T permanent magnet (in the direction of the arrow).
Fig. 4 Longitudinal (&, 1/T1, s
1) and transverse (’, 1/T2, s
1) relaxation
rates as a function of the iron concentration (mM) in (a) g-Fe2O3/PLGA and
(b) (g-Fe2O3/PLGA)/CS NPs, measured at 1.44 T.
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activation, and lysis of erythrocytes,29,85 being responsible for
(i) thrombotic complications and production of anaphylatoxins,
that may activate the immune system;85 and (ii) haemolytic crisis,
that may determine renal damage and anaemia,85,110 respectively.
Table 2 In vitro blood compatibility of the g-Fe2O3/PLGA and (g-Fe2O3/PLGA)/CS particles: haemolysis (%), platelet activation (sP-selectin release, ng mL
1),
complement activation (C3a release: C3a desArg, ng mL1), and plasma recalcification time (T1/2 max, min). Experimental data are expressed as means  SDs of










2 h 4 h 8 h 24 h
g-Fe2O3/PLGA NPs 2.5  0.6 2.5  0.9 2.3  0.8 2.5  0.5 110  8 305  9 14.2  1.1
(g-Fe2O3/PLGA)/CS NPs 2.6  0.8 2.9  0.4 2.6  0.3 2.8  0.6 114  8 306  10 14.3  0.9
Control (PBS solution) 0 0 0 0 97  8 295  7 11.5  1.7
Fig. 5 Representative optical microscopy images of HFF-1 fibroblasts: (a) and (g) are negative controls for the g-Fe2O3/PLGA and (g-Fe2O3/PLGA)/CS
particles, respectively; (b) and (h) are positive controls for the g-Fe2O3/PLGA and (g-Fe2O3/PLGA)/CS NPs, respectively; and HFF-1 cells exposed to (c) g-
Fe2O3/PLGA NPs (100 mg mL
1 of iron) or (i) (g-Fe2O3/PLGA)/CS NPs (100 mg mL
1 of iron). These images show the merge of bright field (grey), DAPI
(blue) and TO-PROs-3 iodide (red). Bar lengths: 100 mm. Total number of cells per well (d and j), dead cells (%, e and k), and relative cell viability (RCV, %)
by MTT assay (f and l) of HFF-1 fibroblasts, after contact with increasing concentrations (0.1 to 100 mg mL1 of iron) of g-Fe2O3/PLGA NPs and (g-Fe2O3/
PLGA)/CS NPs, respectively.
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Data from in vitro blood compatibility tests of g-Fe2O3/PLGA
and (g-Fe2O3/PLGA)/CS NPs is compiled in Table 2. The null
effect on haemolysis (even after 24 h), platelet activation,
complement system activation, and plasma clotting time was
defined. Therefore, these nanocomposites could be character-
ized by an appropriate in vivo safety margin, being suitable for
parenteral administration. Similar results have been obtained
in similar iron oxide-based nanosystems.39–41,87
The results from the cytotoxic evaluation of g-Fe2O3/PLGA
and (g-Fe2O3/PLGA)/CS particles in HFF-1 human foreskin
fibroblast cells are presented in Fig. 5. It is observed how
increasing concentrations, from 0.1 to 100 mg mL1 of iron,
of both core/shell and (core/shell)/shell particles induced
negligible toxicity in the HFF-1 cell line. In fact, they did not
produce significant changes in cell morphology (Fig. 5c and i)
and the total number of HFF-1 cells (Fig. 5d and j), at any of the
concentrations investigated. Moreover, these NP concentra-
tions did not generate a relevant increase in cell death
(Fig. 5e and k). Finally, the RCV (%) of HFF-1 cells remained
Z75%, relative to negative controls, at any of the g-Fe2O3/PLGA
(Fig. 5f) and (g-Fe2O3/PLGA)/CS (Fig. 5l) concentrations ana-
lysed. According to ISO-10993-5,86 these values could be con-
sidered as reasonable and non-toxic.
In vitro magnetic fluid hyperthermia
Antitumour magnetic hyperthermia has proven to be more than
a promising possibility against cancer.29,111–113 The heating
capability of a (core/shell)/shell aqueous magnetofluid in a
high frequency alternating electromagnetic gradient is depicted
in Fig. 6a. The (g-Fe2O3/PLGA)/CS particles transformed into
heaters, possibly owing to the oscillation of their magnetic
moment and magnetic hysteresis losses.29,114 As a conse-
quence, the temperature of the magnetofluid rose from 25 1C
to the minimum hyperthermia temperature (E42 1C, in E32
min). If this temperature is kept constant for E30 min, it has
been described that a tumour mass can be destroyed.114,115
Then, the maximum temperature reached E46 1C after
E50 min, and remained at this temperature until the end of
the experiment (3 h). Considering these results, an appropriate
control over the temperature and heat flux of the magnetofluid
could be postulated. This is a prerequisite for hyperthermia,
particularly when healthy cells surrounding a solid tumour are
damaged when temperature reaches 448 1C.29,116,117
Fig. 6b compiles the results from the evaluation of the
hyperthermic efficacy of the (g-Fe2O3/PLGA)/CS NPs against
T-84 cells. Experimental data proved that compared to controls
the (core/shell)/shell NPs in a high frequency alternating
electromagnetic gradient can significantly reduce cell viability
(up to E39%, group 1) (p o 0.05), thus being postulated to be a
promising nanotool for antitumour magnetic hyperthermia.
Oppositely, when used alone, neither the particles (group 2)
nor the field (group 3) could be considered of any use against
T-84 cells. Finally, in vivo magnetic fluid hyperthermia data
will help in defining clearly the antitumor effect of the
nanostructures.
In vivo MRI
Short-term pharmacokinetics of g-Fe2O3/PLGA (core/shell) NPs
after intravenous injection in Balb/c mice was followed by
dynamic MRI (Fig. 7). Rapid particle uptake by the liver and
spleen was detected (Fig. 7a and b, respectively), with a fast
signal increase of E30% in E5 min in the liver, whereas in the
spleen the increment was slightly more progressive. On the
opposite, NP retention by kidneys could be considered almost
negligible, given that the initial increase in the relative signal
intensity (%) was followed by a fast decrease to baseline
(Fig. 7c). No change in the relative signal intensity (%) was
observed in muscles. These results suggest rapid recognition of
the core/shell particles by the MPS, likely leading to rapid
clearance from the bloodstream by Kupffer cells and splenic
macrophages.
The in vivo fate of the g-Fe2O3/PLGA NPs was further eval-
uated qualitatively by T2-weighted MR images (Fig. 7d–f) and
Fig. 6 (a) Heating curve of an aqueous dispersion of (g-Fe2O3/PLGA)/CS
nanocomposites (&, 10 mg mL1) exposed to a high frequency oscillating
electromagnetic gradient (250 kHz, 4 kA m1), in comparison to data from
a control (i.e. water, K). (b) In vitro hyperthermic efficacy of the magnetic
(core/shell)/shell NPs on T-84 relative cell viability (RCV, %). Experimental
groups are cells incubated in the presence of NPs (0.4%, w/w) with
application of the alternating magnetic field (250 kHz, 4 kA m1) (group 1),
or without application of the alternating magnetic field (control group 2); or
cells incubated in the absence of NPs with application of the alternating
magnetic field (250 kHz, 4 kA m1) (control group 3), or without application
of the alternating magnetic field (control group 4). Experimental data are
expressed as means  SDs of triplicate experiments (n = 3).
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quantitatively by T2-mapping (Fig. 7g) up to 24 h. Liver and
spleen images showed clear hypo-intensity areas at 1 and 24 h
postinjection (Fig. 7e and f, respectively). In contrast, signifi-
cant changes in the kidneys were not observed. Furthermore, a
significant decrease in T2 for the liver (DT2 E 4 ms) and spleen
(DT2 E 5 ms) can be identified in Fig. 7g (p o 0.05) at 1 h
postinjection. By the end of the study (t = 24 h), the absolute
value of DT2 was increased further to E5.4 ms for the liver
(p o 0.05), while being partially recovered in the spleen
(E2.2 ms, p o 0.05). Finally, significant changes in DT2 were
not detected in kidneys or muscles during the study.
The biodistribution of the (g-Fe2O3/PLGA)/CS particles was
found to be quite different from what was described for the
g-Fe2O3/PLGA NPs. The uptake of these (core/shell)/shell nano-
platforms by the liver (Fig. 8a) was lower than that observed for
the g-Fe2O3/PLGA particles (Fig. 7a), given that increments in
Fig. 7 In vivo time courses of g-Fe2O3/PLGA NPs after intravenous injection in Balb/c mice: (a) liver (grey) and muscle (black); (b) spleen (grey) and
muscle (black); and (c) kidney (grey) and muscle (black). Representative T2-weighted MR images of the kidney, spleen, and liver after the injection of the
NPs, at the experimental times: (d) 0 h, (e) 1 h, and (f) 24 h. (g) Absolute values of DT2 (ms) as a function of time (hours) of muscle, liver, spleen and kidney
after the injection of the core/shell NPs. Experimental data are expressed as means  SDs of triplicate experiments (n = 3). The statistical test was
significant for data with *(p o 0.05).
Fig. 8 In vivo time courses of (g-Fe2O3/PLGA)/CS nanocomposites after intravenous injection in Balb/c mice: (a) liver (grey) and muscle (black);
(b) spleen (grey) and muscle (black); and (c) kidney (grey) and muscle (black). Representative T2-weighted MR images of the kidney, spleen, and liver after
the injection of the NPs, at the experimental times: (d) 0 h, (e) 1 h, and (f) 24 h. (g) Absolute values of DT2 (ms) as a function of time (hours) of muscle, liver,
spleen and kidney after the injection of the (core/shell)/shell NPs. Experimental data are expressed as means  SDs of triplicate experiments (n = 3). The
statistical test was significant for data with *(p o 0.05).
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the relative signal intensity (%) values were a little smaller, even
though the r2 value of the former was E30% higher and the
amount injected was the same in both cases.
CS coating onto the (core/shell) nanostructure further
favoured an almost null uptake of the (g-Fe2O3/PLGA)/CS NPs
by the spleen (Fig. 8b). In view of these results, it could be
postulated that CS provided adequate stealth properties to the
nanocomposite,52–55 leading to prolonged blood circulation
times (a relevant attribute for biomedical applications). Simi-
larly to g-Fe2O3/PLGA particles, no change in the relative signal
intensity (%) was observed in kidneys and muscles after intra-
venous injection of the (core/shell)/shell NPs (Fig. 8c).
In vivo distribution data confirmed these findings (Fig. 8d–g). For
instance, increments in the absolute value of DT2 for liver induced
by the (g-Fe2O3/PLGA)/CS NPs (up to E 1.9 ms, p o 0.05, Fig. 8g)
were found to be smaller than those induced by the
g-Fe2O3/PLGA particles (Fig. 7g). These data may ratify that the
uptake of the (core/shell)/shell NPs by the liver was lower than
that observed for the g-Fe2O3/PLGA particles. Quantitative
T2-mapping confirmed the negligible uptake of the (core/shell)/
shell nanostructure by the spleen and muscles found in Fig. 8b,
which may probably the consequence of an almost null inter-
action of the particles with splenic macrophages. Finally, sig-
nificant changes in the absolute value of DT2 were observed for
the kidneys ( p o 0.05), reaching up to E6.1 ms at 24 h
postinjection.
Despite these promising results highlighting the stealthi-
ness of the (g-Fe2O3/PLGA)/CS NPs, experiments in tumour-
bearing mice are needed to better define if magnetically guided
targeting can make possible the selective accumulation of the
(core/shell)/shell particles in the tumour mass.
Ex vivo histology evaluation of iron deposits and toxicity
assessment
PB staining of liver, kidney and lung tissues at 24 h postinjec-
tion of g-Fe2O3/PLGA NPs and (g-Fe2O3/PLGA)/CS in Balb/c mice
is compiled in Fig. 9. Iron deposits in the liver, mainly in
Kupffer cells, were observed after administration of the core/
shell particles, while iron deposits were not detected in kidneys
and lungs. With respect to the (core/shell)/shell nanocompo-
sites, iron deposits were found not only in the liver, but also in
kidneys and lungs. All these findings were in agreement with
the MRI results (see Fig. 7 and 8). This evaluation may support
the hypothesis on the advantageous use of CS if long-
circulating properties are intended for a nanoparticulate
system.52–55 In addition, surface modification with CS has been
described to favour a more extensive biodistribution, e.g. targeting
lung tissue.118
In order to further evaluate the potential toxicity of g-Fe2O3/
PLGA NPs and (g-Fe2O3/PLGA)/CS, H&E staining of liver,
kidney, spleen, lungs and heart tissues at 24 h postinjection
Fig. 9 PB staining of representative histological sections of control liver,
kidney and lung, and liver, kidney and lung at 24 h post-intravenous
injection of g-Fe2O3/PLGA NPs and (g-Fe2O3/PLGA)/CS nanocomposites.
Bar lengths: 100 mm.
Fig. 10 H&E staining of representative histological sections of control liver, kidney, spleen, lung and heart, and liver, kidney, spleen, lung and heart at
24 h post-intravenous injection of g-Fe2O3/PLGA NPs and (g-Fe2O3/PLGA)/CS nanocomposites.

































































































This journal is © The Royal Society of Chemistry 2021 J. Mater. Chem. B, 2021, 9, 4963–4980 |  4975
in Balb/c mice was accomplished (Fig. 10). Vacuolated swelling
of the cytoplasm of hepatocytes, a common indicator of liver
injury, was not found in liver sections. Normal tubular brush
borders and glomeruli (including their surrounding Bowman’s
capsule) were identified in the kidneys. No signs of toxicity were
found also in the spleen, lungs, and heart, independently of the
type of nanoparticulate system [g-Fe2O3/PLGA NPs or (g-Fe2O3/
PLGA)/CS particles].
Combining these data with the results coming from the
in vitro haemocompatibility and cytotoxicity tests (see Section
In vitro haemocompatibility and cytotoxicity), it could be con-
cluded that the nanocomposites present appropriate biocom-
patibility and safety for biomedical use.
Conclusions
A methodology has been described for the reproducible for-
mulation of (g-Fe2O3/PLGA)/CS NPs (E325 nm in size, produc-
tion performance E45%). This (core/shell)/shell nanostructure
was confirmed by electron microscopy and EDX analysis, and
by investigation of the electrokinetic properties. Short-term
stability (up to one month) was demonstrated by size and
surface electric charge determinations. Crystallinity of the
g-Fe2O3 nanocores embedded in the polymer matrix was
demonstrated by X-ray diffraction analysis, with this character-
istic probably being responsible for the adequate magnetic
responsiveness of the nanocomposite (demonstrated in vitro).
In vitro evaluations supported the idea of a potential use of the
(g-Fe2O3/PLGA)/CS particles as T2 contrast agents and in anti-
tumour magnetic hyperthermia. Ex vivo toxicity assessments
and in vitro blood compatibility and cytotoxicity tests postu-
lated the appropriate biocompatibility and safety of the parti-
cles for biomedical use. Finally, in vivo MRI studies and ex vivo
histology determination of iron deposits reinforced the hypoth-
esis on the advantageous use of CS in providing stealth proper-
ties to the nanosystem that may help in retarding the
recognition by the MPS. Taking together, these biocompatible
and long-circulating (core/shell)/shell nanostructures may con-
stitute a potential candidate for theranostic applications (bio-
medical imaging and hyperthermia) against cancer. Additional
experiments in tumour-bearing mice will help in defining if
magnetically guided targeting could make possible the selective
accumulation of the (core/shell)/shell particles in the tumour
mass and the therapeutic effectiveness of this nanoplatform in
cancer hyperthermia therapy.
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39 M. Muñoz de Escalona, E. Sáez-Fernández, J. C. Prados,
C. Melguizo and J. L. Arias, Magnetic solid lipid nano-
particles in hyperthermia against colon cancer, Int.
J. Pharm., 2016, 504, 11–19.
40 C. Lorente, L. Cabeza, B. Clares, R. Ortiz, L. Halbaut,
A. V. Delgado, G. Perazzoli, J. Prados, J. L. Arias and
C. Melguizo, Formulation and in vitro evaluation of mag-
netoliposomes as a potential nanotool in colorectal cancer
therapy, Colloids Surf., B, 2018, 171, 553–565.

































































































This journal is © The Royal Society of Chemistry 2021 J. Mater. Chem. B, 2021, 9, 4963–4980 |  4977
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and A. V. Delgado, Engineering of an antitumor (core/
shell) magnetic nanoformulation based on the chemother-
apy agent ftorafur, Colloids Surf., A, 2011, 384, 157–163.
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Prados, C. Melguizo, L. Cabeza, R. Ortiz and J. L. Arias,
Nano-engineering of 5-fluorouracil-loaded magnetolipo-
somes for combined hyperthermia and chemotherapy
against colon cancer, Eur. J. Pharm. Biopharm., 2013, 85,
329–338.
88 R. Hergt and S. Dutz, Magnetic particle hyperthermia–
biophysical limitations of a visionary tumour therapy,
J. Magn. Magn. Mater., 2007, 311, 187–192.
89 A. P. Khandhar, R. M. Ferguson, J. A. Simon and
K. M. Krishnan, Tailored magnetic nanoparticles for opti-
mizing magnetic fluid hyperthermia, J. Biomed. Mater. Res.,
Part A, 2012, 100, 728–737.
90 E. Fantechi, C. Innocenti, M. Zanardelli, M. Fittipaldi,
E. Falvo, M. Carbo, V. Shullani, L. Di Cesare Mannelli,
C. Ghelardini, A. M. Ferretti, A. Ponti, C. Sangregorio and
P. Ceci, A smart platform for hyperthermia application in
cancer treatment: cobalt-doped ferrite nanoparticles
mineralized in human ferritin cages, ACS Nano, 2014, 8,
4705–4719.
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